Dosing Quetiapine in Drug-Naive First-Episode Psychosis: A Controlled, Double-Blind, Randomized, Single-Center Study Investigating Efficacy, Tolerability, and Safety of 200 mg/day vs. 400 mg/day of Quetiapine Fumarate in 141 Patients Aged 15 to 25 Years
Gregor E Berger, Tina-Marie Proffitt, Mirabel McConchie, Melissa Kerr, Connie Markulev, Hok Pan Yuen, Colin O'Donnell, Dan Lubman, Andrea Polari, Stephen Wood, G Paul Amminger, Patrick D McGorry
JOURNAL OF CLINICAL PSYCHIATRY | PHYSICIANS POSTGRADUATE PRESS | Published : 2008
OBJECTIVE: To assess dosing, efficacy, and tolerability of quetiapine fumarate in drug-naive first-episode psychosis. METHOD: We present a prospective, randomized, controlled, single-center, double-blind, fixed-dose, 4-week comparison study of 200 mg/day versus 400 mg/day of quetiapine in 141 drug-naive acutely ill first-episode psychosis patients (diagnosed according to DSM-IV) aged 15 to 25 years. The double-blind 4-week trial (Part 1) was followed by a single-blind, naturalistic, flexible-dose 8-week period (Part 2). The main outcome measures were symptomatic change, functioning, and tolerability. Data were collected from July 2003 until January 2006. RESULTS: The estimated time trends of..View full abstract
This investigator-initiated trial vas supported by, AstraZeneca Australia and the ORYGEN Research Centre. AstraZeneca reviewed the manuscript prior to publication, made no changes to the manuscript, and put no restrictions on any, of our findings.